Minimal clinically important difference for the historic parts of the Unified Dyskinesia Rating Scale.

Minimal but clinically relevant differences Minimal clinically important changes Parkinson disease Receiver operating characteristic curve Unified Dyskinesia Rating Scale

Journal

Parkinsonism & related disorders
ISSN: 1873-5126
Titre abrégé: Parkinsonism Relat Disord
Pays: England
ID NLM: 9513583

Informations de publication

Date de publication:
01 2019
Historique:
received: 13 05 2018
revised: 08 08 2018
accepted: 24 08 2018
pubmed: 4 9 2018
medline: 3 3 2020
entrez: 4 9 2018
Statut: ppublish

Résumé

Motor complications represent an important clinical problem in the treatment of Parkinson's disease (PD). The Motor Complications Part of the Movement Disorder Society-sponsored Unified Parkinson's Disease Rating Scale (MDS-UPDRS Part IV) and the Unified Dyskinesia Rating Scale (UDysRS) are among the most reliable instruments to evaluate these problems. The minimal clinically important difference thresholds are the smallest changes in the outcome measures that are clinically meaningful. The aim of our study was to calculate the minimal clinically important difference thresholds for the MDS-UPDRS Part IV and the historic parts of the UDysRS. A total of 1044 paired investigations of 436 patients were analyzed. Changes in the respective outcome measures (MDS-UPDRS Part IV, UDysRS Parts I and II) were compared to the Patient-rated Global Impression of Improvement scores (anchors). Subsequently, we applied receiver-operating characteristic analysis to ascertain the MCID thresholds with optimal sensitivity and specificity. Any improvement greater than 2.1 points or any worsening greater than 1.8 points on UDysRS Part I represents a minimal, yet clinically meaningful change. In reference to UDysRS Part II, the smallest changes considered clinically relevant are 1.8 and 1.7 points for improvement and deterioration, respectively. The thresholds for the MDS-UPDRS Part IV are 0.9 points for improvement and 0.8 points for worsening. Our estimates may allow the judgment of the clinical relevance of numeric changes in the dyskinesia scales.

Sections du résumé

BACKGROUND
Motor complications represent an important clinical problem in the treatment of Parkinson's disease (PD). The Motor Complications Part of the Movement Disorder Society-sponsored Unified Parkinson's Disease Rating Scale (MDS-UPDRS Part IV) and the Unified Dyskinesia Rating Scale (UDysRS) are among the most reliable instruments to evaluate these problems. The minimal clinically important difference thresholds are the smallest changes in the outcome measures that are clinically meaningful.
AIMS
The aim of our study was to calculate the minimal clinically important difference thresholds for the MDS-UPDRS Part IV and the historic parts of the UDysRS.
METHODS
A total of 1044 paired investigations of 436 patients were analyzed. Changes in the respective outcome measures (MDS-UPDRS Part IV, UDysRS Parts I and II) were compared to the Patient-rated Global Impression of Improvement scores (anchors). Subsequently, we applied receiver-operating characteristic analysis to ascertain the MCID thresholds with optimal sensitivity and specificity.
RESULTS
Any improvement greater than 2.1 points or any worsening greater than 1.8 points on UDysRS Part I represents a minimal, yet clinically meaningful change. In reference to UDysRS Part II, the smallest changes considered clinically relevant are 1.8 and 1.7 points for improvement and deterioration, respectively. The thresholds for the MDS-UPDRS Part IV are 0.9 points for improvement and 0.8 points for worsening.
CONCLUSIONS
Our estimates may allow the judgment of the clinical relevance of numeric changes in the dyskinesia scales.

Identifiants

pubmed: 30174275
pii: S1353-8020(18)30377-8
doi: 10.1016/j.parkreldis.2018.08.018
pii:
doi:

Substances chimiques

Antiparkinson Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

79-82

Informations de copyright

Copyright © 2018 Elsevier Ltd. All rights reserved.

Auteurs

Attila Makkos (A)

Doctoral School of Clinical Neuroscience, University of Pécs, Pécs, Hungary; Department of Neurology, University of Pécs, Pécs, Hungary.

Márton Kovács (M)

Doctoral School of Clinical Neuroscience, University of Pécs, Pécs, Hungary; Department of Neurology, University of Pécs, Pécs, Hungary.

Dávid Pintér (D)

Doctoral School of Clinical Neuroscience, University of Pécs, Pécs, Hungary.

József Janszky (J)

Department of Neurology, University of Pécs, Pécs, Hungary; MTA-PTE Clinical Neuroscience MR Research Group, Pécs, Hungary.

Norbert Kovács (N)

Department of Neurology, University of Pécs, Pécs, Hungary; MTA-PTE Clinical Neuroscience MR Research Group, Pécs, Hungary. Electronic address: kovacs.norbert@pte.hu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH